Two Phase 3 Trials of Baricitinib for Alopecia Areata

BACKGROUNDAlopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokine signaling implicated in the pathogenesis of alopecia areata. METHODSWe conducted two randomized, placebo-controlled, phase 3 trials (BRAVE-AA1 and …

Continue reading Two Phase 3 Trials of Baricitinib for Alopecia Areata

#Baricitinib reduces 30-day mortality in older adults with moderate-to-severe #COVID-19 pneumonia

Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia. MethodsThis is a propensity …

Continue reading #Baricitinib reduces 30-day mortality in older adults with moderate-to-severe #COVID-19 pneumonia

#Baricitinib plus #Remdesivir for Hospitalized Adults with #Covid-19

Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≀10 days) and either baricitinib (≀14 days) …

Continue reading #Baricitinib plus #Remdesivir for Hospitalized Adults with #Covid-19